HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House version of TSCA reform

This article was originally published in The Rose Sheet

Executive Summary

Reps. Bobby Rush, D-Ill., and Henry Waxman, D-Calif., introduce the Toxic Chemicals Safety Act of 2010 to "strengthen and update" the Toxic Substances Control Act of 1976. H.R. 5820 would place burden on industry to verify a chemical's safety before it can be used. Additionally, legislation would "shine the bright light of public disclosure" on chemicals in consumer products, Rush says in release. Sen. Frank Lautenberg, D-N.J., introduced similar legislation - called the "Safe Chemicals Act" - in the Senate in April (1"The Rose Sheet" April 19, 2010, In Brief)

You may also be interested in...



Toxic Substances Act overhaul proposed

Sen. Frank Lautenberg, D-N.J., chairman of the Subcommittee on Environmental Health, introduces legislation April 15 to overhaul the Toxic Substances Control Act. Lautenberg's Safe Chemicals Act, S. 3209, would require chemical manufacturers, if questioned, to produce data verifying a product's safety in order to keep it on the market. The legislation, which would likely effect a number of personal-care chemicals, including certain fragrances, also would require EPA to establish an interagency panel to select a priority list of 300 chemicals for regulatory review. Lautenberg called for reformation of TSCA at a Senate committee meeting in December (1"The Rose Sheet" Jan. 4, 2010). In a same-day release, the Environmental Working Group says TSCA is "riddled with so many loopholes that in more than 30 years, the [EPA] has been able to regulate only five of the 83,000 chemicals in use in consumer goods.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel